Micro
Emerging
Active
MDCXW Progrès de la FDA et expansion des perspectives cliniques
Nouveau récit avec une couverture limitée — encore en formation.
Score
0,5
Vélocité
▲ 0,0
Articles
1
Sources
1
Chronologie des sentiments
Chronologie des événements
Mai 19, 2026
Medicus Pharma Ltd. (MDCXW) Reports FDA Progress and Expands 2026 Clinical Outlook
Neutral
Hypothèses
Pending
Échéance: 18 juillet 2026
MDCXW trading volume will increase by at least 40% average daily volume in the 30 days following FDA progress announcement compared to 30-day pre-announcement baseline
Pending
Échéance: 15 novembre 2026
MDCXW will complete enrollment for at least one Phase 2 or Phase 3 clinical trial by end of Q2 2026, as evidenced by regulatory filings or company announcements
Pending
Échéance: 17 août 2026
MDCXW stock price will appreciate by at least 15% within 90 days following positive FDA feedback on clinical trial progression announced in Q1 2026
Chronologie
Dernière mise à jourMai 19, 2026